Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(3):416–422. doi: 10.1038/sj.bjc.6690710

Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel

H-L Lin 1,3, T-Y Liu 1,3, C-W Wu 2,4, C-W Chi 1,3
PMCID: PMC2362909  PMID: 10507765

Abstract

Berberine is the major constituent of Coptis chinese and is commonly used in Chinese herbal medicine to treat patients with gastrointestinal disorders. In this study, using flow cytometry, we have found that a 24-h berberine treatment up-regulated the multidrug-resistant transporter (pgp-170) expression in two oral (KB, OC2), two gastric (SC-M1, NUGC-3) and two colon (COLO 205, CT 26) cancer cell lines. Decreased retention of rhodamine 123 was observed in berberine-treated cells as compared to vehicle control. To examine whether the berberine modulated pgp-170 expression in cancer cells is associated with changes in drug resistance, we determined the cytotoxicity, cell cycle progression and cell morphology of Paclitaxel-treated cells. Paclitaxel (1 nM–10 μM) treatment for 24 h induced cytotoxicity in OC2, SC-M1 and COLO 205 cells in a dose-dependent manner. Pretreatment of cells with 32 μM berberine for 24 h prior to Paclitaxel treatment resulted in increased viability as compared to that of Paclitaxel-treated cells. In addition, Paclitaxel-induced apoptosis and/or G2/M arrest in these three cancer cell lines. Pretreatment of cells with berberine prior to Paclitaxel blocked the Paclitaxel-induced cell cycle responses and morphological changes. These results together suggest that berberine modulated the expression and function of pgp-170 that leads to reduced response to Paclitaxel in digestive track cancer cells. © 1999 Cancer Research Campaign

Keywords: oral, gastric and colon cancer cells; pgp-170; berberine; Paclitaxel

Full Text

The Full Text of this article is available as a PDF (620.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akutsu M., Kano Y., Tsunoda S., Suzuki K., Yazawa Y., Miura Y. Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Eur J Cancer. 1995 Dec;31A(13-14):2341–2346. doi: 10.1016/0959-8049(95)00448-3. [DOI] [PubMed] [Google Scholar]
  2. Belani C. P. Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer. Oncology (Williston Park) 1998 Jan;12(1 Suppl 2):74–79. [PubMed] [Google Scholar]
  3. Chang Y. F., Li L. L., Wu C. W., Liu T. Y., Lui W. Y., P'eng F. K., Chi C. W. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer. 1996 Jan 1;77(1):14–18. doi: 10.1002/(SICI)1097-0142(19960101)77:1<14::AID-CNCR4>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  4. Chao Y., Chan W. K., Birkhofer M. J., Hu O. Y., Wang S. S., Huang Y. S., Liu M., Whang-Peng J., Chi K. H., Lui W. Y. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998 Jul;78(1):34–39. doi: 10.1038/bjc.1998.438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chaudhary P. M., Roninson I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991 Jul 12;66(1):85–94. doi: 10.1016/0092-8674(91)90141-k. [DOI] [PubMed] [Google Scholar]
  6. Chi C. W., Chang Y. F., Chao T. W., Chiang S. H., P'eng F. K., Lui W. Y., Liu T. Y. Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sci. 1994;54(26):2099–2107. doi: 10.1016/0024-3205(94)00719-5. [DOI] [PubMed] [Google Scholar]
  7. Cloud-Heflin B. A., McMasters R. A., Osborn M. T., Chambers T. C. Expression, subcellular distribution and response to phorbol esters of protein kinase C (PKC) isozymes in drug-sensitive and multidrug-resistant KB cells evidence for altered regulation of PKC-alpha. Eur J Biochem. 1996 Aug 1;239(3):796–804. doi: 10.1111/j.1432-1033.1996.0796u.x. [DOI] [PubMed] [Google Scholar]
  8. Creasey W. A. Biochemical effects of berberine. Biochem Pharmacol. 1979 Apr 1;28(7):1081–1084. doi: 10.1016/0006-2952(79)90308-3. [DOI] [PubMed] [Google Scholar]
  9. Dumontet C., Duran G. E., Steger K. A., Beketic-Oreskovic L., Sikic B. I. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 1996 Mar 1;56(5):1091–1097. [PubMed] [Google Scholar]
  10. Dustin P. Microtubules. Sci Am. 1980 Aug;243(2):66–76. doi: 10.1038/scientificamerican0880-66. [DOI] [PubMed] [Google Scholar]
  11. Frankel A., Buckman R., Kerbel R. S. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 1997 Jun 15;57(12):2388–2393. [PubMed] [Google Scholar]
  12. Gant T. W., Silverman J. A., Thorgeirsson S. S. Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a trans-acting transcriptional repressor. Nucleic Acids Res. 1992 Jun 11;20(11):2841–2846. doi: 10.1093/nar/20.11.2841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goldstein L. J. MDR1 gene expression in solid tumours. Eur J Cancer. 1996 Jun;32A(6):1039–1050. doi: 10.1016/0959-8049(96)00100-1. [DOI] [PubMed] [Google Scholar]
  14. Jennings B. R., Ridler P. J. Interaction of chromosomal stains with DNA. An electrofluorescence study. Biophys Struct Mech. 1983;10(1-2):71–79. doi: 10.1007/BF00535543. [DOI] [PubMed] [Google Scholar]
  15. Kano Y., Akutsu M., Tsunoda S., Ando J., Matsui J., Suzuki K., Ikeda T., Inoue Y., Adachi K. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer. 1996 Sep;74(5):704–710. doi: 10.1038/bjc.1996.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kano Y., Akutsu M., Tsunoda S., Suzuki K., Yazawa Y. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol. 1996;37(6):525–530. doi: 10.1007/s002800050424. [DOI] [PubMed] [Google Scholar]
  17. Kiehntopf M., Brach M. A., Licht T., Petschauer S., Karawajew L., Kirschning C., Herrmann F. Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J. 1994 Oct 3;13(19):4645–4652. doi: 10.1002/j.1460-2075.1994.tb06787.x. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  18. Kool M., de Haas M., Scheffer G. L., Scheper R. J., van Eijk M. J., Juijn J. A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997 Aug 15;57(16):3537–3547. [PubMed] [Google Scholar]
  19. Kuo C. L., Chou C. C., Yung B. Y. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett. 1995 Jul 13;93(2):193–200. doi: 10.1016/0304-3835(95)03809-b. [DOI] [PubMed] [Google Scholar]
  20. Liebmann J. E., Hahn S. M., Cook J. A., Lipschultz C., Mitchell J. B., Kaufman D. C. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res. 1993 May 1;53(9):2066–2070. [PubMed] [Google Scholar]
  21. Lin H. L., Chang Y. F., Liu T. Y., Wu C. W., Chi C. W. Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. Anticancer Res. 1998 Sep-Oct;18(5A):3443–3449. [PubMed] [Google Scholar]
  22. Lin H. L., Liu T. Y., Lui W. Y., Chi C. W. Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. Cancer. 1999 May 1;85(9):1937–1942. [PubMed] [Google Scholar]
  23. Ludescher C., Thaler J., Drach D., Drach J., Spitaler M., Gattringer C., Huber H., Hofmann J. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol. 1992 Sep;82(1):161–168. doi: 10.1111/j.1365-2141.1992.tb04608.x. [DOI] [PubMed] [Google Scholar]
  24. Milross C. G., Mason K. A., Hunter N. R., Chung W. K., Peters L. J., Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 1996 Sep 18;88(18):1308–1314. doi: 10.1093/jnci/88.18.1308. [DOI] [PubMed] [Google Scholar]
  25. Nishino H., Kitagawa K., Fujiki H., Iwashima A. Berberine sulfate inhibits tumor-promoting activity of teleocidin in two-stage carcinogenesis on mouse skin. Oncology. 1986;43(2):131–134. doi: 10.1159/000226349. [DOI] [PubMed] [Google Scholar]
  26. Pétriz J., García-López J. Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia. 1997 Jul;11(7):1124–1130. doi: 10.1038/sj.leu.2400659. [DOI] [PubMed] [Google Scholar]
  27. Rowinsky E. K., Cazenave L. A., Donehower R. C. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990 Aug 1;82(15):1247–1259. doi: 10.1093/jnci/82.15.1247. [DOI] [PubMed] [Google Scholar]
  28. Rowinsky E. K., Donehower R. C. Taxol: twenty years later, the story unfolds. J Natl Cancer Inst. 1991 Dec 18;83(24):1778–1781. doi: 10.1093/jnci/83.24.1778. [DOI] [PubMed] [Google Scholar]
  29. Rowinsky E. K., Onetto N., Canetta R. M., Arbuck S. G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992 Dec;19(6):646–662. [PubMed] [Google Scholar]
  30. Salvioli S., Ardizzoni A., Franceschi C., Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett. 1997 Jul 7;411(1):77–82. doi: 10.1016/s0014-5793(97)00669-8. [DOI] [PubMed] [Google Scholar]
  31. Schuetz J. D., Strom S. C., Schuetz E. G. Induction of P-glycoprotein mRNA by protein synthesis inhibition is not controlled by a transcriptional repressor protein in rat and human liver cells. J Cell Physiol. 1995 Nov;165(2):261–272. doi: 10.1002/jcp.1041650207. [DOI] [PubMed] [Google Scholar]
  32. Sekiguchi M., Sakakibara K., Fujii G. Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med. 1978 Feb;48(1):61–68. [PubMed] [Google Scholar]
  33. Slichenmyer W. J., Von Hoff D. D. Taxol: a new and effective anti-cancer drug. Anticancer Drugs. 1991 Dec;2(6):519–530. [PubMed] [Google Scholar]
  34. Sun D., Abraham S. N., Beachey E. H. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother. 1988 Aug;32(8):1274–1277. doi: 10.1128/aac.32.8.1274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Taira Z., Matsumoto M., Ishida S., Ichikawa T., Sakiya Y. Aggregation of DNA enhanced by the protoberberine alkaloids, coralyne and berberine. Chem Pharm Bull (Tokyo) 1994 Aug;42(8):1556–1561. doi: 10.1248/cpb.42.1556. [DOI] [PubMed] [Google Scholar]
  36. Vikhanskaya F., Vignati S., Beccaglia P., Ottoboni C., Russo P., D'Incalci M., Broggini M. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res. 1998 May 25;241(1):96–101. doi: 10.1006/excr.1998.4018. [DOI] [PubMed] [Google Scholar]
  37. Watt G., Long G. W., Grogl M., Martin S. K. Reversal of drug-resistant falciparum malaria by calcium antagonists: potential for host cell toxicity. Trans R Soc Trop Med Hyg. 1990 Mar-Apr;84(2):187–190. doi: 10.1016/0035-9203(90)90248-d. [DOI] [PubMed] [Google Scholar]
  38. Wilson L. Microtubules as drug receptors: pharmacological properties of microtubule protein. Ann N Y Acad Sci. 1975 Jun 30;253:213–231. doi: 10.1111/j.1749-6632.1975.tb19201.x. [DOI] [PubMed] [Google Scholar]
  39. Wong D. Y., Chang K. W., Chen C. F., Chang R. C. Characterization of two new cell lines derived from oral cavity human squamous cell carcinomas--OC1 and OC2. J Oral Maxillofac Surg. 1990 Apr;48(4):385–390. doi: 10.1016/0278-2391(90)90436-6. [DOI] [PubMed] [Google Scholar]
  40. Woods C. M., Zhu J., McQueney P. A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1995 Jul;1(5):506–526. [PMC free article] [PubMed] [Google Scholar]
  41. Yang I. W., Chou C. C., Yung B. Y. Dose-dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells. Naunyn Schmiedebergs Arch Pharmacol. 1996 Jul;354(2):102–108. doi: 10.1007/BF00178709. [DOI] [PubMed] [Google Scholar]
  42. Zhang R. X., Dougherty D. V., Rosenblum M. L. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors. Chin Med J (Engl) 1990 Aug;103(8):658–665. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES